Hims & Hers Health, Inc. announced on May 4, 2026, that two members of its Board of Directors will not stand for re-election at the company’s upcoming 2026 annual meeting of stockholders. This decision will result in the board’s size being reduced from eleven to nine members. According to a company filing, the departing directors indicated their decision was not due to any disagreement with the company’s operations, policies, or practices. The reduction in board size is described as part of a broader effort to streamline governance and improve decision-making efficiency as the company scales its specialized health offerings.
The governance shift occurs as Hims & Hers faces a series of new class action lawsuits related to data security. The litigation, filed in multiple jurisdictions, alleges that the company failed to implement adequate safeguards to protect sensitive patient information and health records. Plaintiffs claim that vulnerabilities in the company’s telehealth platform led to unauthorized access to personal data. In an official statement, Hims & Hers defended its security protocols, stating that the company maintains rigorous cybersecurity standards and intends to contest the allegations. The legal challenges come at a time when the company is managing a significant volume of patient data following its expansion into various chronic condition categories.
In addition to legal pressures, Hims & Hers is navigating an increasingly crowded market for GLP-1 weight-loss medications. While the company has seen significant growth in its weight-loss segment over the last two years, competition from both traditional pharmaceutical manufacturers and other telehealth platforms has intensified. Major pharmaceutical companies have recently expanded their own direct-to-consumer distribution models, creating direct competition for the Hims & Hers subscription-based platform. The company reported that while its weight-loss category remains a key revenue contributor, the costs associated with customer acquisition have increased due to the saturation of the digital weight-loss market.
Chief Executive Officer Andrew Dudum stated that the company remains focused on its core mission of providing accessible healthcare while adapting to the current market dynamics. The company’s recent financial disclosures show that it continues to invest in its proprietary technology and pharmacy fulfillment capabilities to maintain a competitive edge. The board’s restructuring is intended to provide a more focused leadership team to oversee these strategic investments and manage the ongoing litigation.
The telehealth sector is also facing evolving regulatory standards regarding the prescription of compounded medications. Hims & Hers has been a prominent provider of compounded GLP-1 treatments during periods of national drug shortages. However, as the supply of branded medications stabilizes, the company is monitoring potential shifts in federal guidance that could affect its product mix. The board reduction and the company’s legal defense strategy are central to its efforts to navigate these regulatory and competitive headwinds.